Eticlopride (10 mg/kg, i.p.) blocks normal vessel morphologyc restored by DA in orthotopic PC3 and HT29 tumor-bearing animals[2].
Eticlopride (0.01 or 0.02 mg/kg, i.p.) alleviates cognitive deficits produced by Quinpirole (HY-B1752) in rats[4].
| Animal Model: | Sprague-Dawley rats treated with Ruinpirole (1 mg/kg) from postnatal days 1 to 21[4] |
| Dosage: | 0.01 or 0.02 mg/kg |
| Administration: | i.p. |
| Result: | Alleviated cognitive deficits produced by neonatal quinpirole treatment in both male and
female rats on the place version of the MWT, as well as in males tested on the match-to-place
version of the MwT (MwT tested on P22 to P28). |
